Dr. David Baker, professor and associate chair of the Department of Biomedical Sciences in the College of Health Sciences at Marquette University, has been awarded the 2013 Way Klingler Fellowship in science for his study of neurotransmitters and their roles in diseases like schizophrenia and addiction.
Baker will receive $50,000 annually for three years for the Way Klingler Fellowship. He believes this opportunity will catalyze increased funding for his research.
“It’s wonderful that the university has this type of intramural support. When done correctly, an investment like this can be leveraged into larger extramural grants, further accelerating the pace of discovery,” Baker said.
Baker’s primary research interest is to understand the contribution of neurotransmitter release from astrocytes to brain function in the normal and diseased states, especially as it relates to schizophrenia and addiction. As a co-founder of Promentis Pharmaceuticals, a start-up company dedicated to discovering pharmacological treatments for neuropsychiatric diseases, Baker has also helped develop novel central nervous system therapeutics, a major emphasis of his program.
“We’re going to improve patient care for people with schizophrenia by understanding the underlying causes, with some of the most powerful techniques used in neuroscience,” he claimed. “It’s research that’s rooted in the mission of Marquette.”
The Way Klingler Fellowships are awarded to full-time regular faculty at the associate or full professor rank who have potential for significant scholarship. One fellowship in science and one in humanities is awarded. The science fellow receives $50,000 annually for three years for research that requires higher-expense items, such as equipment, supplies and research staff.